MedTrace Logo

Acitretin Plasma Levels Under Hemodialysis

NCT00488384 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-07-19

No results posted yet for this study

Summary

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.

Conditions

  • Carcinoma, Squamous Cell

Interventions

DRUG

Chemopreventive application (Acitretin)

Chemopreventive application (Acitretin)

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • Günther Hofbauer

    lead OTHER

Principal Investigators

  • 01 Studienregister MasterAdmins · UniversitaetsSpital Zuerich

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2014-12-31
Completion
2018-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00488384 on ClinicalTrials.gov